The incidence rate of grade 3-4 AEs related to brigatinib was 63.7%, and the most frequent AEs were gastrointestinal reactions, hypertension, cough, headache, and elevated ALT or AST levels (44). The gene discussed is GPT; the disease is Hypertension.